about
Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney DiseasemTOR inhibitors effects on regulatory T cells and on dendritic cellsSirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsMitochondria: a new therapeutic target in chronic kidney diseaseSystemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsSulodexide and glycosaminoglycans in the progression of renal diseasePersonalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineImpact of heparanase on renal fibrosisDownregulation of nuclear-encoded genes of oxidative metabolism in dialyzed chronic kidney disease patientsDirectional dominance on stature and cognition in diverse human populationsMitochondrial dysregulation and oxidative stress in patients with chronic kidney disease.Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen.The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase.A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patientsPharmGKB summary: methotrexate pathway.Karyopherins: potential biological elements involved in the delayed graft function in renal transplant recipients.NLRP3 inflammasome activation in dialyzed chronic kidney disease patients.How has peritoneal dialysis changed over the last 30 years: experience of the Verona dialysis center.Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.Recent data concerning heparanase: focus on fibrosis, inflammation and cancer.Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury.miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.Discovery and refinement of genetic loci associated with cardiometabolic risk using dense imputation maps.Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.mTOR inhibitors and renal allograft: Yin and Yang.New non-renal congenital disorders associated with medullary sponge kidney (MSK) support the pathogenic role of GDNF and point to the diagnosis of MSK in recurrent stone formers.The nephrologist of tomorrow: towards a kidney-omic future.Proteomic-based research strategy identified laminin subunit alpha 2 as a potential urinary-specific biomarker for the medullary sponge kidney disease.Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in IgA nephropathy.Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells.Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity.Specific heparanase inhibition reverses glucose-induced mesothelial-to-mesenchymal transition.Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase.A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.Dialysis-related transcriptomic profiling: the pivotal role of heparanase.Naturally Occurring Compounds: New Potential Weapons against Oxidative Stress in Chronic Kidney Disease.Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation.Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.Dialysis-related systemic microinflammation is associated with specific genomic patterns.In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy.
P50
Q26740125-AE089466-E814-41EE-9ABC-90D509E8D988Q26744447-DD462A52-2E13-45B1-B2AE-78657488B161Q26749011-559BB7C4-7869-4B8A-95BC-E4FA65C2ADC2Q26776397-39BA34FA-5312-40E5-B065-4F39729B891BQ26823023-DBC5A8FA-285F-479F-BBD6-C6C4575CD654Q26991825-3BB16457-2B3F-4B51-AF3D-7A29AB7D3F75Q28082746-95643A9E-FA18-45A8-B26F-4A9B75D18557Q28083753-C7420D42-2626-4883-9CB3-8DF5727D6E48Q28534658-BC64AA6E-5FE6-440B-A4D4-B68C21999AB6Q28646221-DACE5AAF-2667-4659-8EB9-DAB09FE1FD5DQ33495688-28B05BFB-A116-4CF1-A2BA-4BEBBF43A0E1Q33724931-2FB7DA01-E60B-4BC6-AA16-2373012BDBD7Q33724931-826AFA4E-D845-4D5D-9CD8-EB124C968D90Q34457205-58FB7D4E-DCB1-4B49-98F9-D7F5B9408B2AQ34714685-AC373B75-8BB2-4B11-9EFA-2BA024E55BE4Q35115680-D5FD1869-0212-4B57-A1F1-6D4F5ECB3A44Q35119530-66277694-DFD3-4F31-BD0A-663D81F8DDA9Q35208558-D50D2573-1C1A-49CE-AB28-45895AA408AEQ35497673-441A21BD-AC00-4F34-A317-5C898FE34D76Q35775057-BB18149C-70D6-4B6F-B572-4CA5E48CEFE0Q35836200-30076C5D-6A51-43FE-83A5-C830B87D22ADQ36088435-4BDCF4E9-4A19-48C0-B50D-D67417DA3F1AQ36785683-23D11312-7B4F-4FBD-B0C5-1C08C18C67F3Q37613798-80FD4BD1-3376-4EB8-8EC7-C37702ED513EQ37646842-5BDD255B-C890-464D-B65F-0E51AF8A7183Q38209973-00DE6F1E-0EDF-476B-A2F5-5A51BB9DF819Q38749252-0159102E-E4D0-48D0-B591-6238720448F9Q38767679-F76C90BD-E280-4D3F-ABEC-2C1D71ED9433Q38787619-BCA5720C-80FD-4118-B1C5-B783B92500D4Q38796533-826B9AB6-63E7-47CD-8829-102BE2767640Q38866153-FC3B2A36-165B-4A76-9C0C-87C723965397Q38983916-69712708-DED3-455C-A95C-FEF776804A81Q39033979-E7F74F0E-F2B9-421F-AEF0-D94160EFA027Q39060681-3778BB79-A1F4-4770-9A9A-9EB39641375DQ39254044-EFBDBE5E-FD24-4746-A4B4-5AA115E2E927Q39321185-2E3DB9FB-2D96-40BA-95C1-05CEE04DC647Q39429579-967E1758-8C89-4771-96BE-33CCEF5D8595Q39879207-FA70869A-8831-498C-929B-F2BB16BE78D2Q40025515-B9DBF7F2-9BA5-4A1A-A9F2-E4AE15E39535Q40148485-9031CC8C-83BF-45ED-A0D5-7D7351174FE1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gianluigi Zaza
@ast
Gianluigi Zaza
@en
Gianluigi Zaza
@es
Gianluigi Zaza
@nl
Gianluigi Zaza
@sl
type
label
Gianluigi Zaza
@ast
Gianluigi Zaza
@en
Gianluigi Zaza
@es
Gianluigi Zaza
@nl
Gianluigi Zaza
@sl
prefLabel
Gianluigi Zaza
@ast
Gianluigi Zaza
@en
Gianluigi Zaza
@es
Gianluigi Zaza
@nl
Gianluigi Zaza
@sl
P106
P21
P31
P496
0000-0002-6004-6196